Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290915 | 0.80 | KMT2A (0.41) | KMT2AMAPTPOLBGAAMEN1 | |
| SCHEMBL4283120 | 0.78 | CYP1A2 (0.43) | KMT2AGAAMEN1TSHRUSP2 | |
| SCHEMBL4285817 | 0.77 | ALDH1A1 (0.45) | KMT2AMAPTGAAMEN1TSHR | |
| SCHEMBL13705330 | 0.77 | PARP1 (0.52) | MAPTPOLBP2RX7HTT | |
| SCHEMBL4282201 | 0.75 | MAN1B1 (0.38) | MAPTGAAALDH1A1 | |
| SCHEMBL4292964 | 0.73 | MAPT (0.45) | KMT2AMAPTPOLBHTTALDH1A1 | |
| SCHEMBL4283875 | 0.72 | MEN1 (0.42) | KMT2AMAPTPOLBGAAMEN1 | |
| SCHEMBL4295533 | 0.72 | ATM (0.43) | KMT2AMAPTMEN1HTTALDH1A1 | |
| SCHEMBL4293573 | 0.72 | SMN1; SMN2 (0.37) | KMT2APOLBGAAMEN1ALDH1A1 | |
| SCHEMBL4289383 | 0.71 | RAB9A (0.43) | KMT2AMAPTGAAMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KMT2A 1049/4885MAPT 3142/4885POLB 3799/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KMT2A 1049/4885MAPT 3142/4885POLB 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.